Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking

Leukemia

Volumn 29, Issue 1, 2015, Pages 145-156

  Sato, A ^a   Nishida, C ^a   Sato Kusubata, K ^a   Ishihara, M ^a   Tashiro, Y ^a   Gritli, I ^a   Shimazu, H ^a   Munakata, S ^a   Yagita, H ^b   Okumura, K ^b   Tsuda, Y ^c   Okada, Y ^c   Tojo, A ^d   Nakauchi, H ^d   Takahashi, S ^d   Heissig, B ^a,b   Hattori, K ^a,b  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KOBE GAKUIN UNIVERSITY   (Japan)

^d Center for Stem Cell Biology and Regenerative Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; AMINO ACID DERIVATIVE; ANTIFIBRINOLYTIC AGENT; CYTOKINE; FAS LIGAND; GELATINASE B; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMIN; PLASMIN INHIBITOR; TRANEXAMIC ACID; TRANS 4 AMIOMETHYLCYCLOHEXANECARBONYL LEVO (O PICOLYL)TYROSINE 4 AMINOMETHYLANILIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; PRIMER DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE STORM; DISEASE ASSOCIATION; DISEASE SEVERITY; EFFECTOR CELL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LETHALITY; LYMPHOCYTE MIGRATION; MORTALITY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; GRAFT VS HOST DISEASE; METABOLISM; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BASE SEQUENCE; BIOLOGICAL TRANSPORT; CELL LINE; DISEASE MODELS, ANIMAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIN; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX;

EID: 84920701868     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.151     Document Type: Article

References (55)

1. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr. et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998; 102: 1882-1891.
2. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
3. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-581.
4. Yiu HH, Graham AL, Stengel RF. Dynamics of a cytokine storm. PLoS One 2012; 7: e45027.
5. Pinomaki A, Volin L, Joutsi-Korhonen L, Virtanen JO, Lemponen M, Ruutu T et al. Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. Bone Marrow Transplant 2010; 45: 730-737.
6. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004; 61: 873-885.
7. Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, Miles LA. Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT. Blood 2011; 118: 5622-5630.
8. Syrovets T, Jendrach M, Rohwedder A, Schüle A, Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKb-mediated NF-kB activation. Blood 2001; 97: 3941-3950.
9. Ward JR, Dower SK, Whyte MK, Buttle DJ, Sabroe I. Potentiation of TLR4 signalling by plasmin activity. Biochem Biophys Res Commun 2006; 341: 299-303.
10. Li Q, Laumonnier Y, Syrovets T, Simmet T. Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2007; 27: 1383-1389.
11. Burysek L, Syrovets T, Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 2002; 277: 33509-33517.
12. Ohki M, Ohki Y, Ishihara M, Nishida C, Tashiro Y, Akiyama H et al. Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration. Blood 2010; 115: 4302-4312.
13. Tashiro Y, Nishida C, Sato-Kusubata K, Ohki-Koizumi M, Ishihara M, Sato A et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood 2012; 119: 6382-6393.
14. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 2008; 118: 3012-3024.
15. Ishihara M, Nishida C, Tashiro Y, Gritli I, Rosenkvist J, Koizumi M et al. Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metallo-proteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment. Leukemia 2012; 26: 332-339.
16. Heissig B, Lund LR, Akiyama H, Ohki M, Morita Y, Romer J et al. The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell 2007; 1: 658-670.
17. Heissig B, Ohki-Koizumi M, Tashiro Y, Gritli I, Sato-Kusubata K, Hattori K. New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis. Int J Hematol 2012; 95: 131-137.
18. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-557.
19. McGeehan GM, Becherer JD, Bast Jr. RC, Boyer CM, Champion B, Connolly KM et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-561.
20. Bajou K, Peng H, Laug W, Maillard C, Noel A, Foidart J et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14: 324-334.
21. Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T et al. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood 1997; 90: 542-548.
22. Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ikeda S et al. A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation. Bone Marrow Transplant 1999; 23: 1283-1289.
23. Enomoto R, Sugahara C, Komai T, Suzuki C, Kinoshita N, Hosoda A et al. The structure-activity relationship of various YO compounds, novel plasmin inhibitors, in the apoptosis induction. Biochim Biophys Acta 2004; 1674: 291-298.
24. Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A, Okamoto S et al. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors. Chem Pharm Bull (Tokyo) 2001; 49: 1457-1463.
25. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9: 63-79.
26. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S et al. Metall-oproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777-1783.
27. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol 2004; 173: 5467-5475.
28. Schagger H. Tricine-SDS-PAGE. Nat Protoc 2006; 1: 16-22.
29. Lane WJ, Dias S, Hattori K, Heissig B, Choy M, Rabbany SY et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 2000; 96: 4152-4159.
30. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
31. Tagami K, Yujiri T, Takahashi T, Kizuki N, Tanaka Y, Mitani N et al. Increased serum levels of matrix metalloproteinase-9 in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Int J Hematol 2009; 90: 248-252.
32. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571-579.
33. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metal-loproteinases. Crit Rev Biochem Mol Biol 2007; 42: 113-185.
34. Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci USA 1997; 94: 1366-1371.
35. Panoskaltsis-Mortari A, Price A, Hermanson JR, Taras E, Lees C, Serody JS et al. In vivo imaging of graft-versus-host-disease in mice. Blood 2004; 103: 3590-3598.
36. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood 2005; 105: 4191-4199.
37. Hildebrandt GC, Duffner UA, Olkiewicz KM, Corrion LA, Willmarth NE, Williams DL et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 103: 2417-2426.
38. Tieu BC, Lee C, Sun H, Lejeune W, Recinos 3rd A, Ju X et al. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest 2009; 119: 3637-3651.
39. Yao Y, Tsirka SE. The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. J Biol Chem 2010; 285: 31509-31516.
40. Sheehan JJ, Zhou C, Gravanis I, Rogove AD, Wu YP, Bogenhagen DF et al. Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice. J Neurosci 2007; 27: 1738-1745.
41. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13076.
42. Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005; 115: 879-887.
43. Yokoo T, Kitamura M. Dual regulation of IL-1 beta-mediated matrix metallo-proteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 1996; 270(1 Pt 2): F123-F130.
44. Levi M. Activated protein C in sepsis: a critical review. Curr Opin Hematol 2008; 15: 481-486.
45. Gruber A, Marzec UM, Bush L, Di Cera E, Fernandez JA, Berny MA et al. Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood 2007; 109: 3733-3740.
46. Aoki Y, Ota M, Katsuura Y, Komoriya K, Nakagaki T. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopoly-saccharide in rats. Arzneimittelforschung 2000; 50: 809-815.
47. Renckens R, Weijer S, de Vos AF, Pater JM, Meijers JC, Hack CE et al. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004; 24: 483-488.
48. Jourdain M, Carrette O, Tournoys A, Fourrier F, Mizon C, Mangalaboyi J et al. Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am J Respir Crit Care Med 1997; 156: 1825-1833.
49. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med 2012; 40: 2704-2708.
50. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
51. Hoetzenecker W, Echtenacher B, Guenova E, Hoetzenecker K, Woelbing F, Bruck J et al. ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nat Med 2012; 18: 128-134.
52. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511-517.
53. Guo Y, Li J, Hagstrom E, Ny T. Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice. PLoS One 2011; 6: e24774.
54. Walker MJ, McArthur JD, McKay F, Ranson M. Is plasminogen deployed as a Streptococcus pyogenes virulence factor? Trends Microbiol 2005; 13: 308-313.
55. Berri F, Rimmelzwaan GF, Hanss M, Albina E, Foucault-Grunenwald ML, Le VB et al. Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. PLoS Pathog 2013; 9: e1003229.